ABOS — Acumen Pharmaceuticals Share News
0.000.00%
Last trade - 00:00Brief: Acumen Pharmaceuticals - Expects To Complete Enrollment In Intercept-Ad In Q1 Of 2023 & Anticipates Reporting Topline Data From Trial In Q3 Of 2023
Brief: Acumen Pharmaceuticals Appoints Derrell PorterTo Its Board
U.S. RESEARCH ROUNDUP-Calithera Biosciences, Haynes International, Lumos Pharma
Brief: Acumen Pharmaceuticals Reports Third Quarter 2022 Financial Results, Business Highlights
Biogen, Eli Lilly rise after Roche Alzheimer's drug failure
Roche says Alzheimer's drug fails to meet goal in trial (updated)
Brief: Acumen Publishes Phase 1 Trial Design And Clinical Development Plan For Alzheimer’S Disease Antibody
Acumen Pharma up on FDA's 'fast track' tag for Alzheimer's therapy
Brief: Acumen’s ACU193 Granted FDA Fast Track Designation For Alzheimer's Disease
U.S. STOCKS ON THE MOVE-Avantor, energy sector, Acumen
BTIG hikes Acumen's PT on optimism for Alzheimer's drug, shares up
U.S. RESEARCH ROUNDUP-Lumen Technologies, Phillips 66, Westlake
Alzheimer's drug developers soar after Biogen's "unequivocal win"
Biogen, Eisai stocks soar on Alzheimer's success, lifting rival shares (updated)
Brief: Acumen Pharmaceuticals Reports Results For Q2 2022
Brief: Acumen Presents Poster Describing Method To Standardize Amyloid Beta Oligomer Assays Supporting Therapeutic Development For Early Alzheimer’S Disease
Brief: Acumen Pharmaceuticals Inc Files For Mixed Shelf Of Up To $200 Million
U.S. RESEARCH ROUNDUP- Poly, Trean Insurance Group, Volta
Brief: Acumen Pharmaceuticals Reports Financial Results For Full Year Ended December 31